Variety of suitable individuals: CDEC mentioned the uncertainty in the number of sufferers with moderately critical to intense hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who are labeled as possessing delicate or moderate condition can have a serious bleeding phenotype, https://hemgenix17271.theideasblog.com/36307759/not-known-factual-statements-about-hemgenix